

# Jean-Michel Molina

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5607726/publications.pdf>

Version: 2024-02-01

39  
papers

1,748  
citations

471509

17  
h-index

315739

38  
g-index

39  
all docs

39  
docs citations

39  
times ranked

2583  
citing authors

#	ARTICLE	IF	CITATIONS
1	Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults. JAMA - Journal of the American Medical Association, 2018, 320, 379.	7.4	486
2	Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naïve HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet, The, 2008, 372, 646-655.	13.7	442
3	Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection. New England Journal of Medicine, 2020, 382, 1232-1243.	27.0	101
4	Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial. Lancet HIV,the, 2018, 5, e23-e34.	4.7	83
5	A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve HIV-1 patients. Aids, 2018, 32, 1431-1442.	2.2	72
6	Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): a randomised, open-label, phase 3 trial. Lancet Infectious Diseases, The, 2015, 15, 387-396.	9.1	67
7	Complement C5 inhibition in patients with COVID-19 - a promising target?. Haematologica, 2020, 105, 2847-2850.	3.5	53
8	Daily or on-demand oral tenofovir disoproxil fumarate/emtricitabine for HIV pre-exposure prophylaxis. Aids, 2018, 32, 2161-2169.	2.2	45
9	Incidence, risk factors and outcome of multi-drug resistant Acinetobacter baumannii nosocomial infections during an outbreak in a burn unit. International Journal of Infectious Diseases, 2019, 79, 179-184.	3.3	36
10	Pharmacokinetics of Raltegravir in HIV-Infected Patients on Rifampicin-Based Antitubercular Therapy. Clinical Infectious Diseases, 2015, 61, 1328-1335.	5.8	34
11	Infectious Zika virus in vaginal secretions from an HIV-infected woman, France, August 2016. Eurosurveillance, 2017, 22, .	7.0	33
12	Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial. Lancet HIV,the, 2017, 4, e486-e494.	4.7	31
13	Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV Aged 65 Years: Week 48 Results of a Phase 3b, Open-Label Trial. Infectious Diseases and Therapy, 2021, 10, 775-788.	4.0	29
14	Comparison of Tests and Procedures to Build Clinically Relevant Genotypic Scores: Application to the Jaguar Study. Antiviral Therapy, 2005, 10, 479-487.	1.0	24
15	Perspectives of injectable long acting antiretroviral therapies for HIV treatment or prevention: understanding potential users' ambivalences. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2020, 32, 155-161.	1.2	21
16	Immunogenicity and safety of yellow fever vaccine in HIV-1-infected patients. Aids, 2018, 32, 2291-2299.	2.2	20
17	Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trial. Lancet HIV.the, 2019, 6, e655-e666.	4.7	20
18	Safety and efficacy of fumagillin for the treatment of intestinal microsporidiosis. A French prospective cohort study. Journal of Antimicrobial Chemotherapy, 2021, 76, 487-494.	3.0	13

#	ARTICLE	IF	CITATIONS
19	Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1. <i>Aids</i> , 2021, 35, 1061-1072.	2.2	13
20	Doxycycline Prophylaxis for Bacterial Sexually Transmitted Infections: Promises and Perils. <i>ACS Infectious Diseases</i> , 2018, 4, 660-663.	3.8	12
21	Risk factors for invasive pneumococcal disease in HIV-infected adults in France in the highly active antiretroviral therapy era. <i>International Journal of STD and AIDS</i> , 2014, 25, 1022-1028.	1.1	11
22	Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with HIV: Results of a 96-week, phase 3b, open-label, switch trial in virologically suppressed people ≥65 years of age. <i>HIV Medicine</i> , 2023, 24, 27-36.	2.2	11
23	Bladder Cancer in HIV-infected Adults: An Emerging Issue? Case-Reports and Systematic Review. <i>PLoS ONE</i> , 2015, 10, e0144237.	2.5	9
24	Mortality of People Living with HIV in Paris Area from 2011 to 2015. <i>AIDS Research and Human Retroviruses</i> , 2020, 36, 373-380.	1.1	8
25	European confederation of medical mycology expert consultation: An ECMM excellence center initiative. <i>Mycoses</i> , 2020, 63, 566-572.	4.0	8
26	<i>Cryptococcus neoformans</i> meningitis in kidney transplant recipients: A diagnostic and therapeutic challenge. <i>Medical Mycology Case Reports</i> , 2021, 32, 84-87.	1.3	8
27	Detection of microsporidia in surface water: a one-year follow-up study. <i>FEMS Immunology and Medical Microbiology</i> , 2000, 29, 95-100.	2.7	8
28	High efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in people with suppressed HIV and preexisting MR4V/I. <i>Aids</i> , 2022, 36, 1511-1520.	2.2	8
29	Randomized study evaluating the efficacy and safety of switching from an abacavir/lamivudine-based regimen to an elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide single-tablet regimen. <i>Aids</i> , 2019, 33, 1583-1593.	2.2	7
30	Low-dose ritonavir-boosted darunavir in virologically suppressed HIV-1-infected adults: an open-label trial (ANRS 165 Darulight). <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2129-2136.	3.0	5
31	Fosfomycin-trometamol (FT) or fluoroquinolone (FQ) as single-dose prophylaxis for transrectal ultrasound-guided prostate biopsy (TRUS-PB): A prospective cohort study. <i>International Journal of Infectious Diseases</i> , 2021, 102, 269-274.	3.3	5
32	Clinical characteristics, risk factors and outcome of severe Norovirus infection in kidney transplant patients: a case-control study. <i>BMC Infectious Diseases</i> , 2021, 21, 351.	2.9	5
33	Update on French recommendations for the treatment of uncomplicated <i>Neisseria gonorrhoeae</i> infections. <i>International Journal of STD and AIDS</i> , 2021, 32, 1081-1083.	1.1	5
34	Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study. <i>HIV Clinical Trials</i> , 2016, 17, 63-71.	2.0	4
35	Early changes in coagulation but not inflammatory biomarkers under intermittent ART: the randomized ANRS 106 WINDOW trial. <i>Journal of the International AIDS Society</i> , 2014, 17, 19551.	3.0	3
36	<i>Clostridioides difficile</i> infection in solid organ and hematopoietic stem cell transplant recipients: A prospective multinational study. <i>Transplant Infectious Disease</i> , 2022, 24, e13770.	1.7	3

#	ARTICLE	IF	CITATIONS
37	Successful cefiderocol therapy of severe infections due to difficult-to-treat <i>Pseudomonas aeruginosa</i> in two allogeneic hematopoietic stem cell transplantation recipients. <i>Annals of Hematology</i> , 2022, , 1.	1.8	3
38	Bladder cancer in HIV-infected adults: an emerging concern?. <i>Journal of the International AIDS Society</i> , 2014, 17, 19647.	3.0	2
39	ITPA deficiency and ribavirin level are still predictive of anaemia in HCVâ€“HIV-coinfected patients receiving ribavirin combined with a first-generation DAA (ANRS HC27 study). <i>Antiviral Therapy</i> , 2016, 22, 461-469.	1.0	0